The FDA has extended the review period for elinzanetant for the treatment of moderate to severe vasomotor symptoms due to menopause.

Panelists discuss the methodologies of the OASIS 1, 2, and 3 trials that investigated elinzanetant, highlighting key findings regarding its efficacy in reducing the frequency and severity of ...

Elinzanetant significantly reduced vasomotor symptoms (VMS), also known as hot flashes, associated with menopause overall and across a range of body mass index (BMI) and smoking history subgroups ...

Elinzanetant, the first dual neurokinin-1,3 (NK-1,3) receptor antagonist, modulates the KNDy neurons, a group of estrogen sensitive neurons in the hypothalamus region of the brain.

Elinzanetant was associated with fewer and less severe menopausal vasomotor symptoms over 12 weeks. The neurokinin-1,3 receptor antagonist was associated with improved sleep and quality of life vs ...

Elinzanetant statistically significantly reduced the frequency of moderate to severe vasomotor symptoms from baseline to week 4 and 12 vs placebo. Topline results were announced from a phase 3 ...

Bayer's (BAYRY) pipeline candidate, elinzanetant, achieves primary and secondary goals in late-stage OASIS 3 study supporting submissions for marketing authorization.

Following positive topline data for moderate to severe vasomotor symptom treatment, a phase 2 study of elinzanetant is underway to assess its safety and efficacy on sleep disturbances associated ...

The New Drug Application (NDA) for elinzanetant, an investigational compound for the treatment of moderate to severe vasomotor symptoms associated with menopause, is based on the positive data ...

Elinzanetant significantly reduced the frequency and severity of vasomotor symptoms in menopausal women by week 12. The drug also improved sleep disturbances and menopause-related quality of life ...

Elinzanetant is a first dual neurokinin-1,3 (NK-1,3) receptor antagonist, in late-stage clinical development for the non-hormonal treatment of moderate to severe VMS associated with menopause ...